Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer — Aurelius Omlin (2013) | RDL Network
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
Article 2013 en
Authors
AO
Aurelius Omlin
CP
Carmel Pezaro
SZ
S. Zaidi
Abstract
1 min read
Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES). Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded. Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ⩾50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ⩾50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES. Abiraterone has important antitumour activity in men with CRPC even after DES exposure.
Aurelius Omlin, Carmel Pezaro, S. Zaidi, David Lorente, Deborah Mukherji, Diletta Bianchini, Roberta Ferraldeschi, Shahneen Sandhu, David P. Dearnaley, Chris Parker, Nicholas van As, Johann S. de Bono, Gerhardt Attard
Nobuaki Matsubara, Johann S. de Bono, Christopher Sweeney, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Geng Chen, Adam Harris, Fanny Schenkel, Rucha Sane, Healther Hinton, Sergio Bracarda, Cora N. Sternberg
Johann S. de Bono, Josep M. Piulats, Hardev Pandha, Daniel P. Petrylak, Fred Saad, Luis M. Antón Aparicio, Shahneen Sandhu, Peter C.C. Fong, Silke Gillessen, Gary R. Hudes, Tao Wang, J. R. Scranton, Michaël Pollak
Discussion(0)
No comments yet. Be the first to comment.